Patient Leaflet Updated 14-Mar-2024 | ADVANZ Pharma
Epoprostenol 0.5 mg powder and solvent for solution for infusion
Epoprostenol 0.5 mg Powder and Solvent for Solution for Infusion
Epoprostenol (as sodium)
1. What Epoprostenol is and what it is used for
2. What you need to know before you take Epoprostenol
3. How to take Epoprostenol
4. Possible side effects
5. How to store Epoprostenol
6. Contents of the pack and other information
Epoprostenol contains the active substance epoprostenol which belongs to a group of medicines called prostaglandin, which stops blood from clotting and widens the blood vessels.
Epoprostenol is used to treat a lung condition called ‘pulmonary arterial hypertension’. This is where the pressure is high in the blood vessels in the lungs. Epoprostenol widens the blood vessels to lower the blood pressure in the lungs.
Epoprostenol is used to prevent blood clotting during kidney dialysis when heparin cannot be used.
If you think any of these apply to you, don’t take Epoprostenol until you have checked with your doctor.
Before you are given Epoprostenol your doctor needs to know:
Epoprostenol is injected into a vein. It is important that the medicine does not leak out of the vein into the surrounding tissue. If it does, the skin could be damaged. The symptoms of this are:
This may be followed by blistering and shedding of the skin. While you are being treated with Epoprostenol it is important that you check the injection area.
Contact the hospital immediately for advice if the area becomes sore, painful or swollen or you notice any blistering or shedding.
Epoprostenol can cause your heart to beat faster or slower. Also your blood pressure can become too low. While you are being treated with Epoprostenol your heart rate and blood pressure will be checked. The symptoms of low blood pressure include dizziness and fainting.
Tell your doctor if you get these symptoms. Your dose may need to be reduced or your infusion stopped.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Some medicines may affect how Epoprostenol works or make it more likely that you’ll have side effects. Epoprostenol can also affect how some other medicines work if taken at the same time. These include:
Tell your doctor or pharmacist if you are taking any of these.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine as your symptoms could worsen during pregnancy.
It is not known whether the ingredients of Epoprostenol can pass into breast-milk. You should stop breast-feeding your child during treatment with Epoprostenol.
Your treatment may have an effect on the ability to drive or use machinery.
Don’t drive or use machines unless you’re feeling well.
This medicinal product contains 2.43 mmol (or 56 milligram) sodium (salt) per dose. To be taken into consideration by patients on a controlled sodium (salt) diet.
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
Your doctor will decide how much Epoprostenol is right for you. The amount you are given is based on your body weight and your type of illness. Your dose may be increased or decreased depending on how well you respond to treatment.
Epoprostenol is given by slow infusion (drip) into a vein.
Your first treatment will be given to you in a hospital. This is because your doctor needs to monitor you and find the best dose for you.
You will start with an infusion of Epoprostenol. The dose will be increased, until your symptoms are relieved, and any side effects are manageable. Once the best dose has been found, a permanent tube (line) will be fitted into one of your veins. You can then be treated using an infusion pump.
You will be given an infusion of Epoprostenol for the duration of your dialysis.
If you are treating yourself at home, your doctor or nurse will show you how to prepare and use Epoprostenol. They will also advise you how to stop treatment if necessary. Stopping Epoprostenol must be done gradually. It is very important that you follow all their instructions carefully.
Epoprostenol comes as a powder in a glass vial. Before use, the powder needs to be dissolved in the liquid provided. The liquid does not contain a preservative. If you have any of the liquid left over, it must be thrown away.
If you have been fitted with a ‘line’ into a vein it is very important to keep this area clean, otherwise you could get an infection. Your doctor or nurse will show you how to clean your ‘line’ and the area around it. It is very important that you follow all of their instructions carefully.
Seek urgent medical attention if you think you have used or been given too much Epoprostenol. Symptoms of overdose may include headache, nausea, vomiting, fast heart rate, warmth or tingling, or feeling like you might pass out (feeling faint/dizziness).
Do not take a double dose to make up for a forgotten dose.
Stopping Epoprostenol must be done gradually. If the treatment is stopped too quickly you may get serious side effects, including dizziness, feeling weak and breathing difficulties. If you have problems with the infusion pump or injection line that stops, or prevents treatment with Epoprostenol, contact your doctor, nurse or hospital immediately.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Talk to your doctor or pharmacist or nurse about any other side effects, including those not listed in this leaflet.
Very common side effects
These may affect more than 1 in 10 people:
Common side effects
These may affect up to 1 in 10 people:
Common side effects that may show up in blood tests
Uncommon side effects
These may affect up to 1 in 100 people:
Rare side effects
These may affect up to 1 in 1,000 people:
Very rare side effects
These may affect up to 1 in 10,000 people:
It is not known how many people are affected:
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard
By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to the last day of that month.
Powder for solution for infusion:
Keep the vial in the outer carton in order to protect from light.
Keep the vial tightly closed in order to protect from moisture.
Store below 25°C
Solvent:
Keep the vial in the outer carton in order to protect from light.
Store below 25°C
Pulmonary arterial hypertension
Once Epoprostenol powder has been dissolved, and diluted, it should ideally be used immediately. If you are being given Epoprostenol using an infusion pump, a ‘cold pouch’ may be used to maintain the temperature of the solution.
When using a ‘cold pouch’, the solution can be stored in the pump for up to 24 hours at 2-8°C if necessary. The cold pouch must be regularly changed throughout the day, to maintain the temperature of the solution.
If you are not using a ‘cold pouch’, the solution can be stored in the pump:
Renal Dialysis:
Once Epoprostenol has been dissolved and diluted, any unused solution can be stored at 25°C and used within 12 hours.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
Powder for solution for infusion
When 1 vial with 0.5 mg epoprostenol is reconstituted with 50 ml of sterile buffer, the resultant concentration is 10,000 nanograms per ml.
Solvent
Each vial of solvent contains 50 ml of a sterile glycine buffer solution containing approximately 55 milligram sodium.
Epoprostenol is a white lyophilised powder cake packed in clear glass vials with grey lyo stopper and aluminium caps with blue flip-off inserts. The solvent is a clear, colourless solution packed in clear glass vials.
After reconstitution Epoprostenol is a colourless solution, practically free of particles.
Each pack unit contains
Marketing Authorisation Holder
Manufacturer
This medicinal product is authorised in the Member States of the EEA under the following names:
UK: Epoprostenol 0.5 mg Powder and Solvent for Solution for Infusion
Denmark: Epoprostenol ”Campuspharma” 500 mikrogram pulver og solvens til infusionsvæske, opløsning
Norway: Epoprostenol Campuspharma 0,5 mg pulver og væske til infusjonsvæske, oppløsning
Sweden: Epoprostenol CampusPharma 0,5 mg Pulver och vätska till infusionsvätska, lösning
Germany: EPOPROSTENOL PANPHARMA 0,5 mg Pulver und Lösungsmittel zur Herstellung einer Infusionslösung
This leaflet was last revised in February 2024
Dashwood House, 69 Old Broad Street, London, EC2M 1QS, UK
+44 (0)208 588 9131
www.advanzpharma.com
+44 (0)208 588 9131
+44 (0)208 588 9273